Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,961 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,853 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05982873 | Expanded Access to Telisotuzumab Adizutecan | available | — | — | AbbVieINDUSTRY | 0 | Feb 6, 2026 | clinicaltrials |
| NCT03123029 | Expanded Access to Venetoclax | available | — | — | AbbVieINDUSTRY | 0 | Jan 30, 2026 | clinicaltrials |
| NCT07310277 |
| available |
| — |
| — |
| AbbVieINDUSTRY |
| 0 |
| Jan 29, 2026 |
| clinicaltrials |
| NCT06963697 | Expanded Access To Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors | available | — | — | Jaime Leandro Foundation for Therapeutic Cancer VaccinesOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT05619367 | A Compassionate Use (CU) Program of Odronextamab | available | — | — | Regeneron PharmaceuticalsINDUSTRY | 0 | Dec 23, 2025 | clinicaltrials |
| NCT04771078 | Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release | available | — | — | CelgeneINDUSTRY | 0 | Dec 12, 2025 | clinicaltrials |
| NCT04400591 | Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol | available | — | — | Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY | 0 | Dec 11, 2025 | clinicaltrials |
| NCT01881334 | Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants | available | — | — | Joanne Kurtzberg, MDOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT04745637 | Managed Access Programs for INC424, Ruxolitinib | available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Nov 18, 2025 | clinicaltrials |
| NCT07218224 | Expanded Access:18F-Fluorocholine for the Detection of Parathyroid Adenomas | available | — | — | Thomas HopeOTHER | 0 | Oct 20, 2025 | clinicaltrials |
| NCT05974410 | Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients | available | — | — | AVM Biotechnology IncINDUSTRY | 0 | Oct 2, 2025 | clinicaltrials |
| NCT04008524 | A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies | available | — | — | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT06872489 | Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors | available | — | — | Second Life TherapeuticsINDUSTRY | 0 | Jul 23, 2025 | clinicaltrials |
| NCT05650476 | Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076) | available | — | — | PfizerINDUSTRY | 0 | Jun 12, 2025 | clinicaltrials |
| NCT06676891 | Expanded Access Program for GBM Subjects | available | — | — | Rznomics, Inc.OTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT03763370 | Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma | available | — | — | GlaxoSmithKlineINDUSTRY | 0 | Oct 15, 2024 | clinicaltrials |
| NCT04853602 | IFx-Hu2.0 Expanded Access Program | available | — | — | TuHURA Biosciences, Inc.INDUSTRY | 0 | Aug 12, 2024 | clinicaltrials |
| NCT05014607 | Personalized Multi-peptide Vaccination in Combination With the TLR1/2 Ligand XS15 in Cancer Patients(InHeVac01) | available | — | — | University Hospital TuebingenOTHER | 0 | May 9, 2024 | clinicaltrials |
| NCT05119257 | (Bispecific) Antibodies in Cancer Patients(InHeAb01) | available | — | — | University Hospital TuebingenOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06370013 | Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors | available | — | — | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05356312 | Glioblastoma and Individualized Therapies | available | — | — | Zentrum fur Humangenetik TuebingenOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT01590680 | Expanded Access Protocol Using 131I-MIBG | available | — | — | Jubilant DraxImage Inc.INDUSTRY | 1 | Feb 28, 2023 | clinicaltrials |
| NCT05612191 | Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial) | available | — | — | Advenchen Laboratories, LLCINDUSTRY | 0 | Nov 28, 2022 | clinicaltrials |
| NCT04146571 | Expanded Access to Ensartinib for Participants With ALK+ NSCLC | available | — | — | Xcovery Holdings, Inc.INDUSTRY | 1 | Oct 20, 2022 | clinicaltrials |
| NCT05491928 | Treatment of Metastatic Cancer in Terminally Diagnosed Patients | available | — | — | Matrix Biomed, Inc.INDUSTRY | 1 | Sep 1, 2022 | clinicaltrials |
| NCT04960891 | A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp(Non Applicable) | available | — | — | Immunocore LtdINDUSTRY | 0 | Jan 21, 2022 | clinicaltrials |
| NCT04337099 | A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer | available | — | — | Matrix Biomed, Inc.INDUSTRY | 1 | May 5, 2021 | clinicaltrials |
| NCT01317953 | Oral Green Tea Extract for Small Cell Lung Cancer | available | — | — | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT02146066 | Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221(DCVax-L EAP) | available | — | — | Northwest BiotherapeuticsINDUSTRY | 1 | Feb 26, 2016 | clinicaltrials |
| NCT02209441 | Phase I Study of Sorafinib With Folfox4 as First-line Treatment in Advanced/Metastatic Gastric Cancer | available | — | — | Chinese Academy of Medical SciencesOTHER | 0 | Aug 6, 2014 | clinicaltrials |
| NCT01786850 | Magnetic Resonance-guided High-intensity Focused Ultrasound Treatment of Locally Advanced Pancreatic Cancer | available | — | — | University of Roma La SapienzaOTHER | 1 | Jun 18, 2014 | clinicaltrials |
| NCT01267461 | Evaluation of the Proliferative Activities of Insulin Analogues in Primary Human Tumor Cells | available | — | — | Meir Medical CenterOTHER | 0 | Aug 10, 2012 | clinicaltrials |
| NCT01250808 | Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy | available | — | — | Peking UniversityOTHER | 1 | Dec 1, 2010 | clinicaltrials |
| NCT00854841 | The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder | available | — | — | Pusan National University HospitalOTHER | 0 | Mar 3, 2009 | clinicaltrials |
Data updated 22 days agoSource updated Feb 6, 2026source: clinicaltrials